Triple-Action Diabetes Jab Hits Phase 3 Targets, Misses a Key Test

Eli Lilly’s experimental diabetes drug retatrutide cut long-term blood sugar by up to 1.9 percentage points and stripped an average of 11.5 to 15.3 percent of body weight over 40 weeks, according to phase 3 results published in The Lancet on Saturday and simultaneously presented at the American Diabetes Association (ADA) 86th Scientific Sessions in New Orleans. The data come from TRANSCEND-T2D-1, which enrolled 537 adults with inadequately controlled type 2 diabetes and no prior medication, with retatrutide outperforming placebo on HbA1c reduction and body weight at all three tested doses.

The trial, run by Eli Lilly and Company (NYSE: LLY), compared the drug against placebo only. Tirzepatide and semaglutide, the two approved weekly injections that now anchor type 2 diabetes and weight management prescribing, were not in the comparison. Whether retatrutide’s results match, exceed, or fall short of either drug is a question this dataset does not answer.

Double-Digit Weight Loss in a Drug-Naive Population

TRANSCEND-T2D-1 enrolled adults whose blood sugar was inadequately controlled by diet and exercise alone. None had taken any diabetes medication for at least 90 days before entry. All had glycated haemoglobin (HbA1c, the standard marker for long-run blood glucose control) between 7.0% and 9.5%, a body mass index of at least 23 kg/m², and a mean diabetes duration of 2.5 years, placing most participants early in the natural course of the disease. Participants were randomized in roughly equal groups to retatrutide 4 mg, 9 mg, or 12 mg weekly, or placebo, for 40 weeks.

• -1.7 to -1.9 pp: average HbA1c drop across all retatrutide doses, vs. -0.8 pp for placebo
• 11.5% to 15.3%: average body weight lost on retatrutide, vs. 2.6% on placebo
• 36.6 lb: average weight shed on the 12 mg dose over 40 weeks, a 16.8% reduction
• 14 serious adverse events across 537 participants, including 2 in the placebo group

Retatrutide met its primary endpoint of superior HbA1c reduction at every tested dose and cleared all key secondary endpoints. No weight loss plateau appeared through week 40; the trajectory was still declining at the end of the treatment period. Cholesterol levels and blood pressure also improved relative to placebo.

Gastrointestinal side effects were the most common, consistent with other GLP-1 class agents, and eased with time for most participants. Of the 14 serious adverse events, 12 fell in the retatrutide arms and 2 in the placebo group – a low rate for a 40-week study in a metabolically compromised population.

The Glucagon Layer

Every approved weekly drug in this class occupies a progressively larger segment of the metabolic signaling chain. Semaglutide (Ozempic) acts on the GLP-1 receptor alone, suppressing appetite and slowing gastric emptying via the central nervous system. Tirzepatide (Mounjaro) adds GIP (glucose-dependent insulinotropic polypeptide), a second hormone that improves insulin sensitivity and lipid metabolism. Retatrutide adds the glucagon receptor, which in combination with GLP-1 and GIP activation is associated with increased energy expenditure through thermogenesis and fat oxidation in the liver.

Pure glucagon agonism raises blood glucose, which is why its presence in a diabetes drug sounds counterintuitive. In the context of simultaneous GLP-1 and GIP activation, published research suggests that glucagon receptor stimulation produces additive energy expenditure effects – specifically increased liver fat oxidation and thermogenesis – without triggering the hyperglycemic response that a pure glucagon agonist would cause. The earlier signals were striking: in a phase 2 obesity trial published in the New England Journal of Medicine in 2023, the 12 mg dose produced up to 24.2% average body weight loss at 48 weeks, which investigators at the time characterized as the largest weight reduction ever recorded for a glucose-lowering agent. Saturday’s TRANSCEND-T2D-1 results were the first phase 3 pivotal test of that mechanism in a dedicated glycemic setting.

When Diet and Exercise Fall Short

The enrollment criteria define a precise clinical profile. An HbA1c ceiling of 9.5% excluded patients with severely dysregulated diabetes. A floor of 7.0% confirmed that lifestyle management alone was failing. A BMI threshold of at least 23 kg/m² is deliberately lower than most Western trials require, designed to capture Asian and South Asian populations where metabolic disease accumulates at lower body weights. These are patients who have exhausted diet and exercise as their only tools but have not yet been placed on any pharmacological agent.

For that group, an average of 36.6 lb lost over 40 weeks comes alongside improvements in blood pressure and cholesterol that most single-target first-line agents don’t deliver together. The combination matters clinically, because in patients with early type 2 diabetes and obesity, cardiovascular and metabolic risk factors tend to cluster.

Dr Kath McCullough, special adviser on obesity at the Royal College of Physicians, called the results